ABN AMRO Bank N.V. Sells 78,873 Shares of Stryker Corporation $SYK

Key Points

• ABN AMRO Bank N.V. cut its Stryker stake by 11.7% in the fourth quarter, selling 78,873 shares and leaving it with 595,063 shares worth about $208.7 million.
• Stryker’s latest quarterly results missed Wall Street expectations, with earnings of $2.60 per share versus $2.98 expected and revenue of $6.02 billion versus $6.34 billion expected.
• The company also announced a quarterly dividend of $0.88 per share, payable July 31, while analysts still largely remain positive with a consensus rating of Moderate Buy and an average price target of $395.48.

ABN AMRO Bank N.V. decreased its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 11.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 595,063 shares of the medical technology company's stock after selling 78,873 shares during the quarter. Stryker makes up 2.0% of ABN AMRO Bank N.V.'s investment portfolio, making the stock its 18th largest position. ABN AMRO Bank N.V. owned approximately 0.16% of Stryker worth $208,655,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. United Financial Planning Group LLC purchased a new stake in Stryker during the 3rd quarter worth about $27,000. CGC Financial Services LLC purchased a new stake in Stryker during the 4th quarter worth about $29,000. Strive Asset Management LLC purchased a new stake in Stryker during the 3rd quarter worth about $30,000. ANTIPODES PARTNERS Ltd purchased a new stake in Stryker during the 3rd quarter worth about $34,000. Finally, Copia Wealth Management lifted its holdings in Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock worth $40,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SYK. Leerink Partners began coverage on Stryker in a report on Monday, April 13th. They set an "outperform" rating and a $410.00 price objective on the stock. Evercore set a $355.00 price objective on Stryker in a report on Friday, May 1st. Truist Financial reissued a "hold" rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $465.00 price target on shares of Stryker in a report on Wednesday, March 4th. Finally, Barclays lowered their price target on Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a report on Monday, May 4th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $395.48.

Stryker Stock Performance

Shares of NYSE SYK opened at $285.49 on Monday. The stock has a market cap of $109.34 billion, a price-to-earnings ratio of 33.04, a P/E/G ratio of 1.80 and a beta of 0.80. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 1-year low of $284.95 and a 1-year high of $404.87. The stock's 50-day moving average is $340.37 and its 200 day moving average is $355.17.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business's quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker's dividend payout ratio (DPR) is currently 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.